Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay

Cancer Immunology, Immunotherapy

Volumn 61, Issue 12, 2012, Pages 2311-2319

  Akiyama, Yasuto ^a   Komiyama, Masaru ^a   Nakamura, Yoji ^b   Iizuka, Akira ^a   Oshita, Chie ^a   Kume, Akiko ^a   Nogami, Masahiro ^a   Miyata, Haruo ^a   Ashizawa, Tadashi ^a   Yoshikawa, Shusuke ^a   Kiyohara, Yoshio ^a   Yamaguchi, Ken ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b FISHERIES RESEARCH AGENCY   (Japan)

Author keywords

HLA A24 peptide; In silico docking; MAGE antigen; MHC stabilization

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; EPITOPE; HLA A24 ANTIGEN; INTERLEUKIN 12; ISOLEUCYLPHENYLALANYLGLYCYLASPARTYLPROLYLLYSYLLYSYLLEUCYLLEUCINE; ISOLEUCYLPHENYLALANYLSERYLLYSYLALANYLSERYLGLUTAMYLTYROSYLLEUCINE; MELANOMA ANTIGEN; MELANOMA ANTIGEN A12; MELANOMA ANTIGEN A6; PEPTIDE DERIVATIVE; REAGENT; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CELL ASSAY; CELL MATURATION; CELL TYPE; CLINICAL EFFECTIVENESS; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; CULTURE TECHNIQUE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; INTERMETHOD COMPARISON; MELANOMA CELL; MOLECULAR BIOLOGY; MOLECULAR DOCKING; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; VALIDATION STUDY;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A24 ANTIGEN; HUMANS; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84871000810     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1298-1     Document Type: Article

References (24)

1. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: Moving beyond current vaccine. Nat Med 10:909-915
2. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332
3. Matsuda K, Tsunoda T, Tanaka H, Umano Y, Tanimura H, Nukaya I, Takesako K, Yamaue H (2004) Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 53:609-616
4. Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, Song Y, Appella E, Whiteside TL, Deleo AB (2000) A wildtype sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinoma of the head and neck. Clin Cancer Res 6:979-986
5. Ueda Y, Shimizu K, Itoh T, Fuji N, Naito K, Shiozaki A, Yamamoto Y, Shimizu T, Iwamoto A, Tamai H, Yamagishi H (2007) Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides. Jpn J Clin Oncol 37:140-145
6. Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H (2005) Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 65: 4936-4946
7. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(?) progenitor-derived dendritic cell vaccine. Cancer Res 61(17): 6451-6458
8. Akiyama Y, Tanosaki R, Inoue N, Shimada M, Hotate Y, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, Maruyama K, Takaue Y, Yamaguchi K (2005) Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Transl Med 3:4
9. Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E (2011) A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Feb3. doi:10.1002/ijc.25955
10. Tyagi P, Mirakhur B (2009) MAGRIT: The largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 10(5):371-374
11. Tsai JR, Chong IW, Chen YH, Yang MJ, Sheu CC, Chang HC, Hwang JJ, Hung JY, Lin SR (2007) Differential expression profile of MAGE family in non-small-cell lung cancer. Lung Cancer 56(2):185-192
12. Chung FY, Cheng TL, Chang HJ, Chiu HH, Huang MY, Chang MS, Chen CC, Yang MJ, Wang JY, Lin SR (2010) Differential gene expression profile of MAGE family in taiwanese patients with colorectal cancer. J Surg Oncol 102(2):148-153
13. Karn T, Pusztai L, Ruckhaberle E, Liedtke C, Muller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gatje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M (2011) Melanoma antigen family A identified by the biomodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer 48(1):12-23
14. Mailliard RB, Wankowicz-Kakinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P (2004) a-type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity. Cancer Res 64(17): 5934-5937
15. Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, McDonald HA, Gibson GA, Watkins SC, Muthuswamy R, Kalinski P, Okada H (2009) Effective immunotherapy against murine gliomas using rtpe 1 polarizing dendritic cells-significant roles of CXCL10. Cancer Res 69(4):1587-1595
16. Nakamura Y, Tai S, Oshita C, Iizuka A, Ashizawa T, Saito S, Yamaguchi S, Kondo H, Yamaguchi K, Akiyama Y (2011) Analysis of HLA-A24-restricted peptides of carcinoembryonicantigen using a novel structure-based peptide-HLA docking algorithm. Cancer Sci 102(4):690-696. doi:10.1111/j.1349-7006. 2011.01866.x
17. Akiyama Y, Maruyama K, Nara N, Mochizuki T, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, Yamaguchi K (2004) Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail. Anticancer Res 24:571-577
18. Knorr R, Trzeciak A, Bannwarth W, Gillessen D (1989) New coupling reagents in peptide chemistry. Tetrahedron Lett 30: 1927-1930
19. Fujie T, Tahara K, Tanaka F, Mori M, Takesako K, Akiyoshi T (1999) A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int J Cancer 80(2):169-172
20. Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T (1999) Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 5(8):2236-2241
21. Tanaka F, Fujie T, Tahara K, Mori M, Takesako K, Sette A, Celis E, Akiyoshi T (1997) Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocyte antigen-A24. Cancer Res 57:4465-4468
22. Jia ZC, Ni B, Huang ZM, Tian Y, Tang J, Wang JX, Fu XL, Wu YZ (2010) Identification of two novel HLA-A*0201-restricted CTL epitopes derived from MAGE-A4. Clin Dev Immunol Epub 2011 Feb14
23. Jia ZC, Tian Y, Huang ZM, Wang JX, Fu XL, Ni B, Wu YZ (2011) Identification of a new MAGE-A10 antigenic peptide presented by HLA-A*0201 on tumor cells. Cancer Biol Ther 11(4):395-400
24. Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K (2002) Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1,-A2,-A3,-A4,-A6,-A10, and-A12 tumor antigens: Implication in a broad-spectrum tumor immunotherapy. J Immunol 169(1):575-580